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Babesiosis, a common disease of animals, can infect humans via vector “tick bite”, particularly in endemic areas. The recent reports
of fatal cases in Hepatitis C and postliver transplant patients resulting from transfusion of contaminated blood should alert the
medical profession regarding this emerging dilemma in endemic as well as nonendemic areas and the need for accurate blood
screening for transfusion. Here, we illustrate diﬀerent stages of the parasite lifecycle, progression of babesiosis in animal model,
some aspects of pathologic outcomes, ongoing therapeutic modalities, and a feasible Acridine Orange fluorescent methodology
for the diagnostic evaluation of blood samples.

1. Introduction
Human babesiosis, is transmitted by the bite of species “Ixodes” tick (Figure 1) or by the blood transfusion from
an infected individual in North America [1, 2]. Isolated
reports have been documented of possible transplacental
or congenital transmission of babesiosis to neonates [3].
In USA, clinical cases of babesiosis have been reported
primarily in endemic areas, in the Northeast (New England
and New York) to Midwest (Wisconsin and Minnesota), and
California [4–7]. Recent cases from nonendemic area provide
an alert to the medical professions including hepatology
and gastroenterology community regarding emergence of
the potential for transfusing contaminated blood and blood
products with this infectious agent [7–9]. This includes fatal
incident of babesiosis in two patients with the history of
Hepatitis C, blood transfusion, and/or liver transplantation.
Patient a, 43-year-old female from a nonendemic area
(Delaware) was admitted after 3 days of fever, cough, and
fatigue. The patient had been treated with pegylated interferon for 40 weeks and was blood-transfusion-dependent
for the most of her life. She was identified with babesiosis
allegedly resulting from an infection with Babesia microti (B.
microti) after receiving a contaminated blood transfusion.
She was treated with clindamycin/quinine, but patient
expired 3 days after admission [7, 10]. The second case

was a 73-year-old female from Indiana with the history of
liver transplant, splenectomy, and blood transfusion. She was
admitted for fever, dark urine, jaundice, and identified with
6% parasitemia. She was treated with a clindamycin/quinine
combination and additional blood transfusion with no
improvement, and increased parasitemia (50%). The patient
expired 2 days later [8]. Additionally, 57-year-old female
patient with a 26-years history of Crohn’s disease and from
endemic area (Cape Cod, MA) developed a severe fever
(102◦ F) and syncope. She was on antitumor necrotic factor
(anti-TNFα: Infliximab, Remicade) maintenance therapy
(5 mg/kg every 8 weeks) for a period of 10 months and
a history of tick bites. This patient was diagnosed with
15% parasitemia and was treated successfully with atovaquone/azithromycin combination that responded favorably and recovered [6].

2. Babesia microti (B. microti)
Babesia, is an intraerythrocytic protozoan parasite (Figures 2
and 3, blood from experimentally infected hamster with B.
microti) which can cause a spectrum of flu-like symptoms,
including benign headache and fever, in immunocompetent patients. However, in neonates, the elderly, splenectomised, immunocompromised, and AIDS patients [6–14]
as well as animals [15–18], the disease can manifest with
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Figure 1: Scanning electron micrograph of an Ixodes tick larva with
enlarged mouth part (mandibles and hypostome) demonstrating
blade-shaped denticules. Tick inserts denticles into the flesh of the
victim, opens them like an umbrella during blood meal, and infects
the host with babesia (sporozoites).

hepatitis (Figure 4(a), experimentally infected hamster),
hydrothorax, pneumonia (Figure 4(b), infected hamster),
myocarditis, splenomegaly, glomerulonephritis, hematuria,
and hemolytic anemia resulting from fulminating babesiosis
including fatal outcomes if not properly diagnosed and
treated [6–8, 10, 15]. Babesiosis is named after Victor Babes,
a Romanian microbiologist, who discovered the protozoan
parasite in the cattle with febrile hemoglobinuria (1888).

3. Transmission
Babesia has a life cycle similar to malarial organisms with
sexual stage in the vector Ixodes ticks (Figure 1) which transmit the organism. The sexual stage occurs in the tick salivary
glands as extracellular sporozoites and sporoblasts. During a
blood meal, the infested tick inserts its denticles into the flesh
of the victim, opens them like an umbrella, and infects the
host with sporozoites form. Rodents serve as reservoir host,
and humans become accidental host when exposed to the
infested tick in an endemic area. After an infected tick bite,
babesial organisms enter the blood stream and invade the red
blood cells (RBCs) and replicate asexual form as merozoites
(Figures 2, 3(a), and 3(c), blood from infected hamster) and
damage the organs. Parasites and infected RBCs harboring
babesial organisms are picked up by the body immune
cells, including neutrophils (Figures 3(b), 3(d), 3(e), and
3(f), blood from infected hamster), and macrophages and
transferred to the splenic tissue which eventually become
overwhelmed. Man can transmit the parasite by the blood
transfusion, fetal congenital transmission, or infected organ
transplantation [1–4, 15–18].

4. Animal Models
Hamster is a common animal model to study the disease
and to explore drug therapy. Mice usually develop a lowgrade parasitemia and not favored as a model. Hamsters are
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Figure 2: Blood smear, from hamster infected with B. microti,
stained with acridine orange (molecular formula) and examined
with fluorescent microscopy. Babesial organisms appear as singlering forms (Trophozoites) or multinuclei (Merozoites) within the
red blood cells (RBCs). Nuclei (DNA) stain yellow and the rest of
the protein orange red inside the RBCs. RBCs appear as hollow
ghost cells.

inoculated via i.p with an infected blood-harboring babesial
organisms. The disease is usually subacute in hamsters, and
peak parasitemia occurs in 2-3 weeks although infections
may prove to be fatal in about l-2 months after inoculation [16]. Another hamster model was established by B.
microti passaged into immunocompromised animals and
then transitioned into immunocompetent (normal) golden
hamsters [15]. Hamsters were immunosuppressed with one
injection of Depo-Medrol followed by dexamethasone in
daily drinking water. Then the hamsters were inoculated i.p
with the infected blood. This model was found remarkably
similar to the immunocompromised and severe cases of
humans with babesiosis. Similar to acute cases in human,
parasitemia raised rapidly to 70–90% in about 10 days
following the inoculation. The tropism of the organism,
histology, pathogenesis, and response to drugs in this fulminating hamster model was almost identical and mimicked
those parameters in humans [15, 17].

5. Therapies
The clindamycin/quinine combination therapy has been
described in the clearance of parasitemia and resolution of
this disease, although, failures of this treatment approach
have been reported [1, 2, 7–11, 13, 19]. In addition, blood
exchange in severe cases has been shown with a variable
success [7, 8, 10]. Previous studies described the eﬃcacy of
azithromycin/quinine against B. microti in a hamster model
as a possible alternative for the clindamycin/quinine combination [16].
Furthermore, atovaquone was described to be more
eﬀective than the combination of clindamycin/quinine in
prevention as well as therapeutic babesiosis in experimental
studies [17, 18]. In contrast, proguanil (an antimalarial
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Figure 3: (a, b) are scanning electron micrographs and (c–f) transmission electron micrographs from the cross-sections. (a) infected RBCs
from hamster harboring babesial organisms. (b) immune cell (neutrophil) attached to babesial organisms via extended pseudopods. (c)
Cross section of the infected RBC from hamster harboring 2 distinct trophozoites. (d–f) cross-section of neutrophil extending pseudopods
toward extracellular babesia during attachment (d), engulfment (e), and ingestion (f) of the organism (hamster blood).

agent) alone had no eﬀect against the disease in the model
[17, 18]. Currently, atovaquone and azithromycin combination have been reported eﬀective in babesiosis patients from
endemic area [6, 12] as well as those acquired infection via
blood transfusion [1, 7, 20] including neonates [21].
Atovaquone is a 1,4-hydroxynaphthoquinone compound, an analog of ubiquinone, with potent antimalarial
and antipneumocystic activity that has been eﬀective in animals and humans for preventive and therapeutic management of Pneumocystis carinii pneumonitis [22–25], Toxoplasmosis [26], but not cryptosporidiosis [25]. Atovaquone has
been reported, as generally, safe, well tolerated with minor
side eﬀects, and an eﬀective alternative therapy compared
to the clindamycin/quinine combination against babesiosis
in cases [3, 6, 12]. More eﬀective and better-tolerated therapeutic modalities are still needed to prevent possible development of drug resistance in the future.

6. Diagnosis
Patients are usually found to be asplenic, anemic with fever,
and jaundice. Laboratory tests include low hemoglobin, high
total Bilirubin, aspartate aminotransferase (200–7000 IU/L),
creatinine levels, and hemoglobinuria [6–8, 10].
Currently Babesiosis is diagnosed using immunofluorescent assays, enzyme immunoassay EIA, ELISA, RT-PCR, and
microarrays. Babesial immunoglobulin (IgG and IgM titers
by immunofluorescent antibody (IFA) is somehow specific,
and nested polymerase chain reaction (PCR) and real time
to be more sensitive.
Then each case is confirmed using direct blood staining
with Giemsa or Wright staining. For Giemsa staining, thin
blood smears are fixed in methanol and stained for 20 min in
0.5% Giemsa stock solution in 4% PBS. The acridine orange
technique (Figure 4) was found to be rapid and to provide
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Figure 4: Histopathology sections from infected hamsters stained with hematoxylin and eosin. (a) Hepatitis: Hepatic section demonstrates
degeneration of hepatocytes with diﬀuse periportal infiltration of inflammatory cells and bile stasis (brown spots) in parenchyma. (b)
Pneumonitis: pulmonary section with severe edematous, diﬀuse infiltration of inflammatory cells, and hemosiderin deposits (brown spots)
into parenchyma.

a feasible tool and better visualization of B. microti in blood
smears than other direct staining methods. For Acridine
orange staining, blood smears are fixed in methanol and
stained in 0.1% of fluorescent dye diluted in Krebs Ringerphosphate solution pH 7.4 and then examined 10 min later
by fluorescent microscopy [15]. While Giemsa-stained slides
are more stable and can be stored without degradation or
bleaching over long periods, the fluorescent dyes do quench;
however, slides stained with fluorescent dyes can be restained
at a later time with minimal loss of discriminatory power
[15]. Acridine orange is a cell-permeable dye, originally
extracted from coal tar and creosote oil. It is a nucleic
acid selective fluorescent cationic dye that interacts and
binds to DNA of the parasite with a bright yellow-green
light excitation. Acridine orange also sequesters protein
compartments in the cell and becomes protonated to emit
orange light under fluorescent light activation. Acridine
orange technique was found to be a simple and eﬀective
diagnostic tool to confirm babesial infection compared to
other traditionally used direct microscopic examination
techniques, for example, Giemsa and Wright’s stain [15, 18].
Additionally, diﬀerential diagnosis of babesiosis should
be performed with lyme disease, malaria, and other bloodborne diseases using serology, PCR, and direct microscopic
evaluations.
In conclusion, the awareness of the community for a
possible babesial infection, implementation of additional
diagnostic techniques, improved preventive measures, vector
control to interfere with the parasite life cycle, blood and
blood product sanitation, broader screening of the blood
donors and/or blood for transfusion, and eﬀective drug
development should be combined to prevent increases in
babesial infection in endemic as well as nonendemic areas.
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